Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study confirms link between breast density, higher breast cancer risk

2.

FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor

3.

Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma

4.

Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants

5.

Chicken Broth Recall; Medicaid at Risk; Princess Kate Thanks Medical Staff


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot